II. Indications
III. Contraindications
- See Fibric Acid Derivative
- Avoid in Serum Creatinine >=2 mg/dl
IV. Dosing
- Take 600 mg orally twice daily at 30 minutes before meals
V. Efficacy
- See Fibric Acid Derivative
- No Fibrate has been shown to reduce all cause mortality
- Gemfibrozil is the only Fibrate shown to decrease cardiovascular events
- NNT to prevent one coronary event: 46-125
VI. Adverse Effects
VII. Safety
- Pregnancy Category C
- Unknown safety in Lactation
VIII. Drug Interactions
- See Fibric Acid Derivative
- Avoid with specific other medications
- Statins (esp. Simvastatin)
- Dasabuvir
- Repaglinide
- Increases levels of other medications
- CYP2C8 Substrates (e.g. Montelukast, Paclitaxel, Pioglitazone)
- OATP1B1 Substrates (e.g. Ezetimibe, Glyburide, Olmesartan, Rifampin)
- Warfarin
IX. Resources
Images: Related links to external sites (from Bing)
Related Studies
gemfibrozil (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GEMFIBROZIL 600 MG TABLET | Generic | $0.10 each |
Ontology: Gemfibrozil (C0017245)
Definition (NCI) | A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C). |
Definition (MSH) | A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. |
Definition (CSP) | lipid regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. |
Concepts | Pharmacologic Substance (T121) , Lipid (T119) |
MSH | D015248 |
SnomedCT | 35282000, 387189002 |
LNC | LP15168-5, MTHU002557 |
English | Gemfibrozil, Gemfibrosil, Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-, gemfibrozil, gemfibrozil (medication), gemfibrozil (Lopid), GEMFIBROZIL, Gemfibrozil [Chemical/Ingredient], gemfibrosil, Gemfibrozil product, Gemfibrozil (product), Gemfibrozil (substance) |
Swedish | Gemfibrozil |
Czech | gemfibrozil |
Finnish | Gemfibrotsiili |
Russian | GEMFIBROZIL, ГЕМФИБРОЗИЛ |
Japanese | ジェムフィブロジィル, ゲムフィブロジル, ゲンフィブロジル |
Spanish | genfibrocil (producto), gemfibrozilo (producto), genfibrocil, Gemfibrozil, gemfibrozilo (sustancia), gemfibrozilo, gemfibrozil, genfibrocil (sustancia), Gemfibrozilo |
Italian | Gemfibrosil, Gemfibrozil |
French | Gemfibrosil, Gemfibrozil |
Polish | Gemfibrozil |
Croatian | Gemfibrozil |
Portuguese | Genfibrozil, Genfibrozila |
German | Gemfibrozil |